The purpose of our study was to review the evidence for the efficacy of surveillance for early
detection, bilateral prophylactic mastectomy, prophylactic oophorectomy and …

Purpose Chemoprevention with a selective estrogen receptor modulator (tamoxifen or
raloxifene) is a non-surgical option offered to high-risk women to reduce the risk of breast …

ContextAmong cancer-free women aged 35 years or older, tamoxifen reduced the incidence
of estrogen receptor (ER)–positive but not ER-negative breast cancer. The effect of …

Several options for cancer prevention are available for women with a BRCA1 or BRCA2
mutation, including prophylactic surgery, chemoprevention and screening. The authors …

Purpose: The purpose of this study was to assess women's knowledge about tamoxifen, to
examine the frequency of tamoxifen usage and other preventive measures in BRCA1/2 …

Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of
approximately 80%. Tamoxifen treatment of the first cancer has been associated with a …

BRCA1 and BRCA2 breast cancer predisposition gene mutation carriers are at markedly
increased risk of breast and other cancers. The consideration of chemopreventative options …

Background: BRCA1 and BRCA2 gene mutations carry with them a 50%–80% risk of
developing breast cancer. The best choice for managing breast cancer risk in patients with a …

BACKGROUND. Women who are at increased risk for breast and ovarian cancers,
especially BRCA1 and BRCA2 mutation carriers, face a myriad of risk‐reduction options …

The development of breast cancer control strategies in women at high genetic risk of breast
cancer is an important issue. The likely benefit of chemopreventive approaches is of …